<unk> , or<unk> -HD-AraC (<unk> ituximab plus (H)igh (D)ose (A)ra-(C)) is a chemotherapy<unk> egimen that is used, alternating with<unk> -Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody<unk> ituximab and high-dose antimetabolite cytarabine. High-dose Ara-C <unk>  without<unk> ituximab also has several other uses in oncohematology. For example,<unk> , alone or alternating with HD-MTX, is often used for primary CNS lymphoma and for treating CNS involvement in any lymphomas, and also for so-called "CNS prophylaxis" (prophylactic use in those forms of lymphoma which show no signs of CNS involvement at diagnosis but have high chance of CNS<unk> elapse or<unk> ecurrence).<unk>  is also used as a consolidation<unk> egimen in acute myeloid leukemia after initial 7+3 induction.<unk>  also can be used as the primary induction therapy in AML, with higher than in 7+3 success <unk> emission)<unk> ate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary induction therapy.
R-HDAC
C-KAD
QS-21
CURB-65
Gamma probe
CARB-X
TRNA 
SOS box